Revelation Biosciences, Inc. announced a 1-for-3 reverse stock split of its common stock, which will become effective on July 7, 2025. This corporate action was approved at a Special Meeting of Stockholders held on June 23, 2025. The company's common stock will trade on a post-split basis under its existing trading symbol 'REVB' starting on the effective date.
The primary objective of this reverse stock split is to increase the market price per share of the company’s common stock. This is intended to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, and stock options.
Separately, the company also announced that its ongoing PRIME Phase 1b clinical study of Gemini in CKD patients is expected to complete enrollment this month. Topline data from this study is anticipated shortly after the completion of enrollment. This clinical update provides a positive counterpoint to the financial restructuring.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.